June 23, 2010

HELIX BIOPHARMA CORP. ANNOUNCES POSITIVE PHASE II (PDF)

(AURORA, Ontario) – Helix BioPharma Corp. (TSX, FSE: “HBP” / OTCQX: HXBPF) today announced positive Phase II pharmacokinetic (“PK”) findings for Topical Interferon Alpha-2b in patients with low-grade cervical
lesions.